

Registered number: 02774777

ACAMBIS RESEARCH LIMITED

ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2019



ACAMBIS RESEARCH LIMITED

COMPANY INFORMATION

Directors	F X Duhalde H Fry
Registered number	02774777
Registered office	410 Thames Valley Park Drive Reading Berkshire RG6 1PT
Independent Auditor	Ernst & Young LLP Statutory Auditors Apex Plaza Forbury Road Reading RG1 1YE

ACAMBIS RESEARCH LIMITED

CONTENTS

	Page
Strategic report	1 - 3
Directors' report	4
Directors' responsibilities statement	5
Independent auditor's report	6 - 8
Statement of comprehensive income	9
Balance sheet	10
Statement of changes in equity	11
Notes to the financial statements	12 - 21

ACAMBIS RESEARCH LIMITED

STRATEGIC REPORT FOR THE YEAR ENDED 31 DECEMBER 2019

Introduction

The directors present their strategic report for Acambis Research Limited ("the company") for the year ended 31 December 2019.

Principal activities and review of business

The company does not trade and its sole source of income is interest receivable on an inter-group current account balance.

The key financial performance indicators during the year were as follows:

	2019	2018	%
	£000	£000	change
Operating (loss)/profit	(1)	(289)	100
Shareholders' funds	46,325	46,108	0

Operating loss for 2019 is due to administration costs.

Shareholders' funds remained broadly in line with the prior year.

Principal risks and uncertainties

The company's operations expose it to a variety of risks that include the effects of changes in price risk, liquidity risk, interest rate risk and foreign exchange risk. The company complies with the Sanofi (the company's ultimate parent undertaking) policies and risk management program that seeks to limit the adverse effect of these risks on the company. In order to ensure stability of cash outflows and hence manage interest rate risk for the group, Sanofi manages the risk of fluctuation of interest rates on behalf of all companies within the group and uses derivative financial instruments to do this.

Price risk

The company is not materially exposed to commodity price risk as a result of its operations, and therefore believes that the costs of managing these risks outweigh any potential benefit. The directors will revisit the appropriateness of this policy should the company's level of exposure materially increase in the future. The company has no exposure to equity securities price risk as it holds no listed or other equity investments.

Liquidity risk

The company is financed through intercompany current and loan accounts and also has in place arrangements with Sanofi to ensure the availability of sufficient funds for the company's ongoing operations, should additional funds be required for operations or planned expansions.

Interest rate cash flow risk

The company has interest bearing assets and liabilities. Short term interest bearing assets include amounts receivable from other group undertakings within the United Kingdom, which earn interest at LIBOR minus 5 basis points. Short term interest bearing liabilities include amounts payable from other group undertakings within the United Kingdom, which incur interest at LIBOR plus 15 basis points.

No interest is charged on balances due to or receivable from fellow dormant undertakings within the United Kingdom.

ACAMBIS RESEARCH LIMITED

STRATEGIC REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2019

Principal risks and uncertainties (continued)

Foreign exchange risk

Sanofi operates a foreign exchange risk hedging policy to reduce the exposure of operating income to fluctuations in foreign currencies, particularly the US dollar and the Euro but also other currencies where required. In order to mitigate these fluctuations the company is required to enter into derivative contracts with Sanofi. The policy involves regular assessments of the group's worldwide foreign currency exposure, based on budget estimates of foreign-currency transactions to be carried out by the parent company and its subsidiaries. These transactions mainly comprise sales, purchases, research costs, co-marketing and co-promotion expenses, and royalties. To reduce the exposure of these transactions to exchange rate movements, Sanofi contracts economic hedges using liquid financial instruments such as forward purchases and sales of currency.

COVID-19

As the COVID-19 pandemic rapidly spread across the globe earlier this year, Sanofi formed a global crisis team to tackle an unknown virus that had already spread around the world. The team's main focus was on ensuring the ongoing manufacture and supply of its vaccines, treatments for dozens of diseases and keeping employees safe with new sanitary measures. In parallel, Sanofi started figuring out how to deploy its resources to fight the coronavirus.

Early on, along with the worldwide healthcare community, Sanofi considered a range of options to attack COVID-19, initiating tests on existing treatments, while its vaccines unit, Sanofi Pasteur, began studying the new virus and forging strategic partnerships to pool science, expertise and resources. Today, with more information on the virus, it has become clear that the most effective way to a post-pandemic world are safe and effective vaccines.

Sanofi recently announced the continuation of its work in COVID-19 vaccine development with the start of a phase 1 and 2 clinical trial, in partnership with GSK. The trial will enrol 440 healthy adults in the US to evaluate the vaccine's safety, tolerability and immune response. The aim is to deliver the first results by December. Positive data would enable a prompt start of a pivotal phase 3 trial by the end of this year. A positive outcome from phase 3 trials could mean a request for regulatory approval in the first half of 2021.

The COVID-19 vaccine candidate is being tested using vital ingredients from both Sanofi and GSK. Sanofi is developing the antigen (the protein that stimulates the body's immune response against the virus), which is based on recombinant DNA technology. Sanofi is using an existing technology that was designed for influenza and is applying it to the new virus that causes COVID-19 disease. Having the existing platform and partnerships are key to finding the optimal vaccine that will have impact against disease while contributing to vast and urgent global demand.


GSK is contributing an adjuvant, an ingredient added to enhance the immune response, which reduces the amount of vaccine protein required per dose and improves the chances of delivering an effective vaccine that can be manufactured at scale.

Sanofi is also exploring a second COVID-19 vaccine candidate, in partnership with Translate Bio, a clinical-stage messenger RNA (mRNA) biotechnology company. The project is on track to start clinical trials by December.

ACAMBIS RESEARCH LIMITED

**STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2019**

This report was approved by the board and signed on its behalf.

A handwritten signature in black ink, appearing to read 'F X Duhalde', with a large, stylized initial 'F'.

F X Duhalde
Director

Date: 11 December 2020

ACAMBIS RESEARCH LIMITED

DIRECTORS' REPORT FOR THE YEAR ENDED 31 DECEMBER 2019

The directors present their report and the financial statements of Acambis Research Limited ("the company") for the year ended 31 December 2019.

Directors

The directors who served during the year and up to the date of this report were:

F X Duhalde
H Fry

Research and development activities

The company incurred no research and development costs in the current year (2018 - £Nil) following the sale of intellectual property on the HSV, Replivax and Rhinovirus vaccines in December 2015.

Going concern statement

The COVID-19 pandemic has not created significant operational and financial pressures on the company. Having considered the contingency plans in place, the support to businesses announced by the UK Government and having reviewed updated cashflow forecasts, the directors consider the adoption of the going concern basis in preparing these financial statements is appropriate.

Furthermore, the directors have also received confirmation from Sanofi, the ultimate parent company, of its intention to support the company for a period of at least 12 months from the date of signing the accounts and so, on that basis, the directors have a reasonable expectation that the company will have adequate financial resources to continue in operation for the foreseeable future. For this reason, the directors continue to adopt the going concern basis in preparing the financial statements.

Disclosure of information to auditor

Each of the persons who are directors at the time when this Directors' report is approved has confirmed that:

- so far as that director is aware, there is no relevant audit information of which the company's auditor is unaware, and
- that director has taken all the steps that ought to have been taken as a director in order to be aware of any relevant audit information and to establish that the company's auditor is aware of that information.

Auditor

The auditor, Ernst & Young LLP, will be proposed for reappointment in accordance with section 485 of the Companies Act 2006.

Small companies note

In preparing this report, the directors have taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006.

This report was approved by the board and signed on its behalf.



F X Duhalde
Director

Date: 11 December 2020

ACAMBIS RESEARCH LIMITED

**DIRECTORS' RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2019**

The directors are responsible for preparing the Strategic report, the Directors' report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 101 'Reduced Disclosure Framework'. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF ACAMBIS RESEARCH LIMITED

Opinion

We have audited the financial statements of Acambis Research Limited for the year ended 31 December 2019, which comprise the Statement of Comprehensive Income, Balance sheet, Statement of Changes in Equity and the related notes 1 to 14, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards including Financial Reporting Standard 101 'Reduced Disclosure Framework' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 31 December 2019 and of its profit for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of matter

We draw attention to Notes 2.3 and 13 of the financial statements, which describes the economic and social disruptions the company is facing as a result of COVID-19 which is impacting its supply chains, consumer demand and personnel available for work and or being able to access offices. Our opinion is not modified in respect of this matter.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the directors' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the directors have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF ACAMBIS RESEARCH LIMITED
(CONTINUED)**

Other information

The other information comprises the information included in the Annual Report set out on pages 1 to 5, other than the financial statements and our Auditor's report thereon. The directors are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Strategic report and the Directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Strategic report and the Directors' report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic report or the Directors' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF ACAMBIS RESEARCH LIMITED (CONTINUED)

Responsibilities of directors

As explained more fully in the Directors' responsibilities statement on page 5, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditor's report.

Use of our report

This report is made solely to the company's members in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an Auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members for our audit work, for this report, or for the opinions we have formed.

Ernst & Young LLP

Jane S Turnor (Senior statutory auditor)

for and on behalf of
Ernst & Young LLP

Statutory Auditors

11 December 2020

ACAMBIS RESEARCH LIMITED

**STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2019**

	Note	2019 £000	2018 £000
Other operating charges		(1)	(289)
Operating loss	4	(1)	(289)
Interest receivable and similar income	6	311	252
Profit/(loss) before tax		310	(37)
Tax (charge)/credit for the year	7	(93)	16
Profit/(loss) for the financial year		217	(21)
Total comprehensive income/(expense) for the year		217	(21)

The above results were derived from continuing operations.


The notes on pages 12 to 21 form part of these financial statements.

ACAMBIS RESEARCH LIMITED
REGISTERED NUMBER: 02774777

BALANCE SHEET
AS AT 31 DECEMBER 2019

	Note	2019 £000	2018 £000
Current assets			
Debtors	8	46,328	46,229
		<u>46,328</u>	<u>46,229</u>
Creditors: amounts falling due within one year	9	(3)	(121)
Net current assets		<u>46,325</u>	<u>46,108</u>
Total assets less current liabilities		<u>46,325</u>	<u>46,108</u>
Net assets		<u>46,325</u>	<u>46,108</u>
Capital and reserves			
Share capital	11	-	-
Profit and loss account	12	46,325	46,108
Total equity		<u>46,325</u>	<u>46,108</u>

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:



F X Duhalde
Director

Date: 11 December 2020

The notes on pages 12 to 21 form part of these financial statements.

ACAMBIS RESEARCH LIMITED

**STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2019**

	Share capital £000	Profit and loss account £000	Total equity £000
At 1 January 2019	-	46,108	46,108
Comprehensive income for the year			
Profit for the year	-	217	217
Total comprehensive income for the year	-	217	217
At 31 December 2019	-	46,325	46,325

**STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2018**

	Share capital £000	Profit and loss account £000	Total equity £000
At 1 January 2018	-	46,129	46,129
Comprehensive income for the year			
Loss for the year	-	(21)	(21)
Total comprehensive loss for the year	-	(21)	(21)
At 31 December 2018	-	46,108	46,108

The notes on pages 12 to 21 form part of these financial statements.

ACAMBIS RESEARCH LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2019

1. Authorisation of financial statements and statement of compliance with FRS 101

The financial statements of Acambis Research Limited ("the company") for the year ended 31 December 2019 were authorised for issue by the board of directors on 11 December 2020, and the Balance Sheet was signed on the board's behalf by F X Duhalde. The company is a private company limited by shares and is incorporated and domiciled in England. The address of the registered office is 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT.

These financial statements were prepared in accordance with Financial Reporting Standard 101 'Reduced Disclosure Framework' ("FRS 101").

The company's financial statements are presented in Sterling and all values are rounded to the nearest thousand pounds (£000) except when otherwise indicated.

The results of the company are included in the consolidated financial statements of Sanofi (20F) which are available on the corporate website.

The principal accounting policies adopted by the company are set out in note 2.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared on a going concern basis, under the historical cost convention, unless otherwise specified within these accounting policies, and in accordance with FRS 101 and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 101 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the company's accounting policies (see note 3).

The accounting policies which follow set out those policies which apply in preparing the financial statements for the year ended 31 December 2019.

ACAMBIS RESEARCH LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2019

2. Accounting policies (continued)

2.2 Financial reporting standard 101 - reduced disclosure exemptions

The company has taken advantage of the following disclosure exemptions under FRS 101:

- the requirements of IFRS 7 Financial Instruments: Disclosures
- the requirements of paragraphs 91-99 of IFRS 13 Fair Value Measurement
- the requirement in paragraph 38 of IAS 1 'Presentation of Financial Statements' to present comparative information in respect of:
 - paragraph 79(a)(iv) of IAS 1;
 - paragraph 73(e) of IAS 16 Property, Plant and Equipment;
 - paragraph 118(e) of IAS 38 Intangible Assets;
- the requirements of paragraphs 10(d), 10(f), 16, 38A, 38B, 38C, 38D, 40A, 40B, 40C, 40D, 111 and 134-136 of IAS 1 Presentation of Financial Statements
- the requirements of IAS 7 Statement of Cash Flows
- the requirements of paragraphs 30 and 31 of IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors
- the requirements of paragraph 17 and 18A of IAS 24 Related Party Disclosures
- the requirements in IAS 24 Related Party Disclosures to disclose related party transactions entered into between two or more members of a group, provided that any subsidiary which is a party to the transaction is wholly owned by such a member
- the requirements of paragraphs 130(f)(ii), 130(f)(iii), 134(d)-134(f) and 135(c)-135(e) of IAS 36 Impairment of Assets.

2.3 Going concern

The COVID-19 pandemic has not created significant operational and financial pressures on the company. Having considered the contingency plans in place, the support to businesses announced by the UK Government and having reviewed updated cashflow forecasts, the directors consider the adoption of the going concern basis in preparing these financial statements is appropriate.

Furthermore, the directors have also received confirmation from Sanofi, the ultimate parent company, of its intention to support the company for a period of at least 12 months from the date of signing the accounts and so, on that basis, the directors have a reasonable expectation that the company will have adequate financial resources to continue in operation for the foreseeable future. For this reason, the directors continue to adopt the going concern basis in preparing the financial statements.

2.4 Debtors

Short term debtors are measured at transaction price, less any provision for impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

ACAMBIS RESEARCH LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2019

2. Accounting policies (continued)

2.5 Creditors

Creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers.

2.6 Financial instruments

Financial assets

The company classifies all of its financial assets as loans and receivables.

Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They arise principally through the provision of goods and services to customers (e.g. trade receivables), but also incorporate other types of contractual monetary asset. They are initially recognised at fair value plus transaction costs that are directly attributable to their acquisition or issue, and are subsequently carried at amortised cost using the effective interest rate method, less provision for impairment.

Impairment provisions are recognised when there is objective evidence (such as significant financial difficulties on the part of the counterparty or default or significant delay in payment) that the company will be unable to collect all of the amounts due under the terms receivable, the amount of such a provision being the difference between the net carrying amount and the present value of the future expected cash flows associated with the impaired receivable. For trade receivables, which are reported net, such provisions are recorded in a separate allowance account with the loss being recognised within administrative expenses in the Statement of Comprehensive Income. On confirmation that the trade receivable will not be collected, the gross carrying value of the asset is written off against the associated provision.

Financial liabilities

The company classifies all of its financial liabilities as liabilities at amortised cost.

At amortised cost

Financial liabilities at amortised cost including bank borrowings are initially recognised at fair value net of any transaction costs directly attributable to the issue of the instrument. Such interest bearing liabilities are subsequently measured at amortised cost using the effective interest rate method, which ensures that any interest expense over the period to repayment is at a constant rate on the balance of the liability carried into the Balance sheet.

ACAMBIS RESEARCH LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2019

2. Accounting policies (continued)

2.7 Foreign currency translation

Functional and presentation currency

The company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the Statement of Comprehensive Income except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of Comprehensive Income within 'finance income or costs'. All other foreign exchange gains and losses are presented in the Statement of Comprehensive Income within 'other operating income'.

2.8 Interest income

Interest income is recognised in the Statement of Comprehensive Income using the effective interest method.

ACAMBIS RESEARCH LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2019

2. Accounting policies (continued)

2.9 Current and deferred taxation

Current tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities, based on tax rates and laws that are enacted or substantively enacted by the Balance Sheet date.

Deferred income tax is recognised on all temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements, with the following exceptions:

deferred income tax assets are recognised only to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, carried forward tax credits or tax losses can be utilised.

Deferred income tax assets and liabilities are measured on an undiscounted basis at the tax rates that are expected to apply when the related asset is realised or liability is settled, based on tax rates and laws enacted or substantively enacted at the Balance Sheet date.

The carrying amount of deferred income tax assets is reviewed at each Balance Sheet date. Deferred income tax assets and liabilities are offset only if: a legally enforceable right exists to set off current tax assets against current tax liabilities, the deferred income taxes relate to the same taxation authority and that authority permits the company to make a single net payment.

Income tax is charged or credited to Other Comprehensive Income if it relates to items that are charged or credited to Other Comprehensive Income. Similarly, income tax is charged or credited directly to equity if it relates to items that are charged or credited directly to equity. Otherwise income tax is recognised in the Statement of Comprehensive Income.

3. Judgements in applying accounting policies and key sources of estimation uncertainty

The preparation of financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported for assets and liabilities as at the Balance Sheet date and the amounts reported for revenues and expenses during the year. However, the nature of estimation means that actual outcomes could differ from those estimates.

No judgements were applied that had a significant effect on amounts recognised in the financial statements.

4. Operating loss

The operating loss is stated after charging:

	2019 £000	2018 £000
Exchange differences	-	327

Auditors' remuneration of £5,000 (2018 - £4,000) was borne by another group company in the current year.

ACAMBIS RESEARCH LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2019**

5. Employees

The average monthly number of employees, including the directors, during the year was as follows:

	2019 No.	2018 No.
Directors	2	2

There are no employees other than the directors.

Directors' emoluments are paid by another group company. Directors' services to the company and to a number of group undertakings are of a non-executive nature and their emoluments are deemed to be wholly attributable to their services to other group undertakings. Accordingly no directors' remuneration is paid by the company.

6. Interest receivable

	2019 £000	2018 £000
Interest receivable from group undertakings	311	252

7. Taxation

	2019 £000	2018 £000
Corporation tax		
Adjustments in respect of previous periods	34	-
Group taxation relief	59	(16)
Total current tax credit	93	(16)
Deferred tax		
Total deferred tax	-	-
Taxation on profit/(loss) on ordinary activities	93	(16)

ACAMBIS RESEARCH LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2019**

7. Taxation (continued)**Factors affecting tax charge for the year**

The tax assessed for the year is higher than (2018 - *lower than*) the standard rate of corporation tax in the UK of 19% (2018 - 19%). The differences are explained below:

	2019 £000	2018 £000
Profit/(loss) on ordinary activities before tax	310	(37)
Profit on ordinary activities multiplied by standard rate of corporation tax in the UK of 19% (2018 - 19%)	59	(7)
Effects of:		
Expenses not deductible for tax purposes, other than goodwill amortisation and impairment	-	(9)
Adjustments to tax charge in respect of prior periods	34	-
Group relief (claimed)/surrendered	(59)	16
Payment/(receipt) for group relief	59	(16)
Total tax charge for the year	93	(16)

The company has unrecognised tax losses amounting to £13,284,000 (2018 - £13,284,000) that are available indefinitely for offset against future taxable profits of the company. Deferred tax assets have not been recognised in respect of these losses as there is uncertainty over the recoverability.

ACAMBIS RESEARCH LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2019**

7. Taxation (continued)

Factors that may affect future tax charges

A reduction in the UK corporation tax rate from 19% to 17% (effective from 1 April 2020) was substantively enacted on 6 September 2016.

On 20 March 2020, a special provision was substantively enacted which removed the 17% corporate tax rate and reinstated the 19% corporation tax rate.

The deferred tax included in the company balance sheet is as follows:

	2019	2018
	£000	£000
Accelerated capital allowances	-	-
Tax losses carried forward	2,258	2,258
Tax losses carried forward unrecognised	(2,258)	(2,258)
	<u>-</u>	<u>-</u>
	<u>-</u>	<u>-</u>

8. Debtors

	2019	2018
	£000	£000
Amounts owed by group undertakings	46,328	46,195
Other debtors	-	34
	<u>46,328</u>	<u>46,229</u>

The amounts owed by group undertakings are unsecured, and repayable on demand. Amounts relating to trading balances owed by non-UK companies and balances owed by dormant companies are interest free. All other balances carry interest at LIBOR minus 5 basis points.

ACAMBIS RESEARCH LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2019**

9. Creditors: Amounts falling due within one year

	2019	2018
	£000	£000
Trade creditors	1	1
Amounts owed to group undertakings	2	120
	<u>3</u>	<u>121</u>

The amounts owed to group undertakings are unsecured, and repayable on demand. Amounts relating to trading balances owed to non-UK companies and balances owed to dormant companies are interest free. All other balances carry interest at LIBOR plus 15 basis points.

10. Financial instruments

	2019	2018
	£000	£000
Financial assets		
Financial assets that are debt instruments measured at amortised cost	<u>46,328</u>	<u>46,229</u>
Financial liabilities		
Financial liabilities measured at amortised cost	<u>(3)</u>	<u>(121)</u>

Financial assets measured at amortised cost comprise amounts owed by group undertakings and other debtors.

Financial liabilities measured at amortised cost comprise trade creditors, amounts owed to group undertakings and other creditors.

11. Share capital

	2019	2018
	£000	£000
Allotted, called up and fully paid		
2 (2018 - 2) Ordinary shares of £1.00 each	<u>-</u>	<u>-</u>

12. Reserves

Profit & loss account

The profit and loss account represents the accumulated profits, losses and distributions of the company.

ACAMBIS RESEARCH LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2019

13. Post balance sheet events

On 11 March 2020, the World Health Organization raised the public health emergency caused by the coronavirus outbreak (COVID-19) to an international pandemic. The rapid evolution of the facts, at national and international level, represents an unprecedented health crisis, which will impact on the macroeconomic environment and the evolution of business.

While the potential impact of the coronavirus emergency is uncertain, the company considers that these events do not imply an adjustment in the annual accounts for the year ended 31 December 2019.

Given the complexity of the situation and its rapid evolution, it is not practicable at this time to reliably make a quantified estimate of its potential impact on the company, which, where appropriate, will be recorded prospectively in the annual accounts for the 2020 financial year.

The company is carrying out appropriate efforts to deal with the situation and according to the most current estimates and the position of treasury to date, this does not compromise the application of the principle of business continuity.

14. Ultimate parent undertaking and controlling party

The immediate parent undertakings at the Balance Sheet date are Life Science Holdings Inc. and Sanofi Pasteur Biologics LLC, companies incorporated in the USA, by virtue of their 50/50 share holding in the company. The ultimate parent undertaking and controlling party is Sanofi, a company incorporated in France. Sanofi is the parent undertaking of the largest and smallest group of undertakings to consolidate these financial statements at 31 December 2019. The consolidated financial statements of Sanofi, are available from: Sanofi, 54, Rue La Boetie, 75008 Paris, France.